|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 美国临床肿瘤学会IV期非小细胞肺癌化疗的临床实践指南更新显示文摘本文旨在为IV期非小细胞肺癌患者的治疗提供更新版推荐。本文资料检索源自2002年以来公布的相关随机试验文献。此指南范围限于化疗与生物治疗。更新委员会对这些文献进行了总结并提供了推荐更新。162篇文献符合标准被纳入参考。本推荐基于可改善总生存期的治疗方法。仅改善无进展生存期的治疗方法推动了对毒性及生存质量的监测。对于体力状态评分为0分或1分患者的一线治疗,可推荐以铂类为基础的细胞毒性药物的两药联用。对铂类治疗有禁忌的患者,可采用非铂类细胞毒性两药联合。对于体力状态评分为2分的患者,单一细胞毒性药物即可。对于疾病进展或经过4个周期的治疗仍对治疗无反应的患者,应停止一线细胞毒性化疗。即使在6个周期后患者对治疗仍有反应,亦应停止两药细胞毒性化疗。对于伴有明确的表皮生长因子受体(epidermal growth factor receptor,EGFR)突变的患者,可推荐一线采用吉非替尼治疗;对于EGFR突变为阴性或不明确的患者,细胞毒性化疗更佳。除具有特定临床特征的患者外,可推荐贝伐单抗与卡铂-紫杉醇联用。对于通过免疫组化证实EGFR阳性的肿瘤患者,可推荐西妥昔单抗与顺铂-长春瑞滨联用。多西紫杉醇、厄洛替尼、吉非替尼或培美曲塞被推荐作为二线治疗。对于未曾接受过厄洛替尼或吉非替尼治疗的患者,可推荐厄洛替尼作为三线治疗。现有数据不足以推荐常规三线采用细胞毒性药物。已有的证据也不足以推荐常规应用分子标记物选择化疗。 | Christopher G. AZZOLI Sherman Baker JR Sarah TEMIN William PAO Timothy ALIFF Julie BRAHMER David H. JOHNSON Janessa L. LASKIN Gregory MASTERS Daniel MILTON Luke NORDQUIST David G. PFISTER Steven PIANTADOSI Joan H. SCHILLER Reily SMITH Thomas J. SMITH John R. STRAWN David TRENT Giuseppe GIACCONE 丁燕(翻译) 南娟(翻译) 刘谦(翻译) 周清华(校对) 陈军(校对) | 2010 | 中国肺癌杂志2010，13，3： | 43 |
| 2 | Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab显示文摘 | H.A. Wakelee S.E. Dahlberg J.R. Brahmer J.H. Schiller M.C. Perry C.J. Langer A.B. Sandler C.P. Belani D.H. Johnson | 2011 | Lung Cancer2011，，3： | 3 |
| 3 | 伺服冲压技术在数控转塔冲床中的创新与应用显示文摘本文针对数控转塔冲床的伺服冲压技术发展趋向,通过对SVR伺服电机驱动主传动专利技术、DECV阀技术的伺服液压系统,以及有关转盘模具库与转模专利新技术的介绍,使读者进一步了解当前国内外伺服驱动主传动式数控转塔冲床的技术动态与进展,也对探知未来高性能板材冲压加工设备的技术发展提供些许有益的参考。 | 李兵 Bert Brahmer 王立勤 王菁华 宋志强 魏志国 张建设 | 2014 | 锻压装备与制造技术2014，49，1： | 3 |
| 4 | Targeting the Immune System in the Treatment of Non-Small-Cell Lung Cancer显示文摘 | Deepa Rangachari Julie R. Brahmer | 2013 | Current Treatment Options in Oncology2013，，4： | 2 |
| 5 | ECOG 4599 phase Ⅲ trial of carboplatin and paclitaxel ± bevacizumab: Subset analysis of survival by gender显示文摘 | BRAHMER JR GRAY R SCHILLER JH | 2006 | Proc Am Soc Clin Oncol2006，24，： | 1 |
| 6 | Who Should Receive Epidermal Growth Factor Receptor Inhibitors for Non - Small Cell Lung Cancer and When? 显示文摘 | Hann CL Brahmer JR | 2007 | Curt Treat Options Oncol2007，8，1： | 1 |
| 7 | Clinical cancer advances 2009: major research advances in cancer treatment, pre vention, and scrccning-A report from the American society of clinical oncology显示文摘 | PETRELLI N J WINER EP BRAHMER J | 2009 | J Clin Oncol2009，27，35： | 1 |
| 8 | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl J Med2012，366，26： | 1 |
| 9 | Harnessing the immune system for the treatment of non-small-cell lung cancer 显示文摘 | BRAHMER J R | 2013 | J Clin Oncol2013，31，8： | 1 |
| 10 | Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis显示文摘 | Ariel Lopez-Chavez Todd Young Sophie Fages Larry Leon Joan H. Schiller Afshin Dowlati Julie R. Brahmer David H. Johnson Alan Sandler | 2012 | Journal of Thoracic Oncology2012，，11： | 1 |
| 11 | CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors 显示文摘 | Li J Karlsson MO Brahmer J | 2006 | J Natl Cancer lnst2006，98，23： | 1 |
| 12 | Retrospective evaluation of the clinical and ra-diographic risk factors associated with severe pulmonary hemorrhage in first-line advanced,unresectable non-small cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab显示文摘 | Sandler AB Schiller JH Gray R Dimery I Brahmer J Samant M Wang LI Johnson DH | 2009 | J Clin Onco2009，27，9： | 1 |
| 13 | Safety and activi- ty of Anti-PD-LI antibody in patients with advanced can- cer显示文摘 | Brahmer JR Tykodi SS Chow LQ | 2012 | N Engl J Med2012，366，26： | 1 |
| 14 | Clinical cancer advances 2009:Major research advances in cancer treatment,prevention,and screening-A report from the American Society of Clinical Oncology显示文摘 | Nicholas J Petrelli Eric P Winer Julie Brahmer | 2009 | JCO2009，26，： | 1 |
| 15 | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl J Med2012，366，26： | 1 |
| 16 | Safety,activity, and immune con'elates of Anti-PD-I antibody in cancer显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl J Med2012，366，26： | 1 |
| 17 | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer 显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | N Engl J Med2012，366，26： | 1 |
| 18 | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non- Small-Cell Lung Cancer显示文摘 | Brahmer J Reckamp KL Baas P | 2015 | N Engl J Med2015，373，2： | 1 |
| 19 | Safety,activity,and immunecorrelates of anti-PD-1 antibody in cancer显示文摘 | Topalian SL Hodi FS Brahmer JR | 2012 | Engl J Med2012，366，26： | 1 |
| 20 | Phase I study of single-agent anti-programmed death-1(MDX-1106)in refractory solid tumors:safety,clinical activity,pharmacodynamics,and immunologic correlates显示文摘 | Brahmer JR Drake CG Wollner I | 2010 | J Clin Oncol2010，28，19： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员